Management and challenges of thyroid cancer treatment with radioiodine therapy in a patient with cerebral palsy and autism spectrum disorder: a case report
DOI:
https://doi.org/10.15392/2319-0612.2026.3006Keywords:
Case report, Radioiodine therapy, Papillary thyroid carcinoma, Autism spectrum disorder, Radiation protectionAbstract
Background: Thyroid cancer is one of the most prevalent endocrine neoplasms in Brazil, and radioiodine therapy (RAI) is a well-established adjuvant treatment. However, managing RAI can be particularly challenging in patients with neurological disorders and significant behavioral disturbances. Case Presentation: We report the case of a 16-year-old adolescent with cerebral palsy and level 3 autism spectrum disorder (ASD) who underwent RAI after total thyroidectomy for metastatic papillary thyroid carcinoma. The case illustrates the tailored technical and clinical strategies implemented by the multidisciplinary team to address the patient’s complex needs, including adaptations in radiation protection, hospitalization logistics, and caregiver support. Conclusion / Lessons Learned: This case underscores the complexity of performing RAI in patients with severe neurological and behavioral impairments. It reinforces the importance of early and expanded multidisciplinary involvement—particularly from neurology and psychiatry—during the preparatory phase. Additionally, enhanced caregiver training and consideration of alternative therapeutic strategies are essential to ensure safety, optimize radiological protection, and improve adherence throughout the treatment process.
Downloads
References
[1] SUNG, H. et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA: a cancer journal for clinicians, v. 71, n. 3, p. 209–249, maio 2021. DOI: https://doi.org/10.3322/caac.21660
[2] BALOCH, Z. W. et al. Overview of the 2022 WHO Classification of Thyroid Neoplasms. Endocrine Pathology, v. 33, n. 1, p. 27–63, mar. 2022. DOI: https://doi.org/10.1007/s12022-022-09707-3
[3] BRASIL. Instituto Nacional de Câncer, Estimativa 2023: incidência de câncer no Brasil. Rio de Janeiro, RJ: Instituto Nacional De Câncer, 31 mar. 2023. Disponível em: <https://www.inca.gov.br/sites/ufu.sti.inca.local/files/media/document/estimativa-2023.pdf>. Acesso em: 30 set. 2024.
[4] CHANDEKAR, K. R.; SATAPATHY, S.; BAL, C. Impact of radioiodine therapy on recurrence and survival outcomes in intermediate-risk papillary thyroid carcinoma -A systematic review and meta-analysis. Clinical Endocrinology, v. 100, n. 2, p. 181–191, 2023. DOI: https://doi.org/10.1111/cen.15001
[5] SPARANO, C. et al. Strategies for Radioiodine Treatment: What’s New. Cancers, v. 14, n. 15, p. 3800, 4 ago. 2022. DOI: https://doi.org/10.3390/cancers14153800
[6] SCUFFHAM, J. W. et al. Radioiodine retention on percutaneous endoscopic gastrostomy tubes. The British Journal of Radiology, v. 85, n. 1012, p. e76–e78, abr. 2012. DOI: https://doi.org/10.1259/bjr/20832147
[7] WANG, X. et al. The benefits of radioactive iodine ablation for patients with intermediate-risk papillary thyroid cancer. PLOS ONE, v. 15, n. 6, p. e0234843, 15 jun. 2020. DOI: https://doi.org/10.1371/journal.pone.0234843
[8] BIBBO, G. et al. Radioiodine (131I) therapy in a child with autism spectrum disorder: A complex and demanding task. World Journal of Nuclear Medicine, v. 18, n. 03, p. 293–295, jul. 2019. DOI: https://doi.org/10.4103/wjnm.WJNM_40_18
[9] GAGNIER, J. J. et al. The CARE guidelines: consensus-based clinical case report guideline development. Journal of Clinical Epidemiology, v. 67, n. 1, p. 46–51, jan. 2014. DOI: https://doi.org/10.1016/j.jclinepi.2013.08.003
[10] AMERICAN THYROID ASSOCIATION. Management Guidelines for Children with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Pediatric Thyroid Cancer. Thyroid, v. 25, n. 7, p. 716–759, jul. 2015. DOI: https://doi.org/10.1089/thy.2014.0460
[11] LEBBINK, C. A. et al. 2022 European Thyroid Association Guidelines for the management of pediatric thyroid nodules and differentiated thyroid carcinoma. European Thyroid Journal, v. 11, n. 6, p. e220146, 1 dez. 2022. DOI: https://doi.org/10.1530/ETJ-22-0146
Downloads
Published
Issue
Section
License
Copyright (c) 2026 Dra. Janaína Dutra Silvestre Mendes, Beatriz Trajano Coelho, Claudia Maria Teixeira Palhota Menezes, Marcia Maria Santos Lopes de Andrade, Célia Helena Fernandes da Costa
This work is licensed under a Creative Commons Attribution 4.0 International License.
Licensing: The BJRS articles are licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/
